Mark E Reeves
Overview
Explore the profile of Mark E Reeves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu Y, Li S, Xiao J, Liu Q, Cherukuri D, Liu Y, et al.
Drug Resist Updat
. 2025 Jan;
79:101199.
PMID: 39823827
Chromosomal rearrangements (CR) initiate leukemogenesis in approximately 50 % of acute myeloid leukemia (AML) patients; however, limited targeted therapies exist due to a lack of accurate molecular and genetic biomarkers...
2.
Cao H, Xiao J, Baylink D, Nguyen V, Shim N, Lee J, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457563
T-cell-based adoptive cell therapies have emerged at the forefront of cancer immunotherapies; however, failed long-term survival and inevitable exhaustion of transplanted T lymphocytes in vivo limits clinical efficacy. Leukemia blasts...
3.
Freeman H, Mudgway R, Tran Z, Kim R, Lum S, Namm J, et al.
Surg Endosc
. 2024 Aug;
38(11):6854-6864.
PMID: 39179690
Background: Studies have demonstrated comparable outcomes between laparoscopic and open resection of gastrointestinal stromal tumor (GIST). We sought to compare outcomes among robotic, laparoscopic, and open resection of gastric GIST...
4.
Xu Y, Baylink D, Xiao J, Tran L, Nguyen V, Park B, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39126100
Acute myeloid leukemia (AML) has a poor survival rate for both pediatric and adult patients due to its frequent relapse. To elucidate the bioenergetic principle underlying AML relapse, we investigated...
5.
Chen W, Williams T, So L, Drew N, Fang J, Ochoa P, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673926
Acute myeloid leukemia (AML) is a hematological malignancy that is characterized by an expansion of immature myeloid precursors. Despite therapeutic advances, the prognosis of AML patients remains poor and there...
6.
Pairawan S, Dominguez C, Solomon N, Caba-Molina D, OLeary M, Reeves M, et al.
JAMA Surg
. 2024 Jan;
159(3):347-349.
PMID: 38231528
No abstract available.
7.
Xu Y, Baylink D, Chen C, Tan L, Xiao J, Park B, et al.
Front Oncol
. 2023 Nov;
13:1286863.
PMID: 38023123
Acute myeloid leukemia (AML) patients have frequent mutations in FMS-like receptor tyrosine kinase 3 (FLT3-mut AML), who respond poorly to salvage chemotherapies and targeted therapies such as tyrosine kinase inhibitors...
8.
Castillo D, Jeon W, Park D, Pham B, Yang C, Joung B, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511306
In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose...
9.
Bush D, Volk M, Smith J, Reeves M, Sanghvi S, Slater J, et al.
Cancer
. 2023 Jul;
129(22):3554-3563.
PMID: 37503907
Background: This study compares survival rates, recurrence patterns, toxicity, and treatment cost in patients with hepatocellular carcinoma (HCC) treated with either transarterial chemoembolization (TACE) or proton beam radiotherapy (PBT). Methods:...
10.
Liu T, Chen Z, Chen W, Evans R, Xu J, Reeves M, et al.
Precis Clin Med
. 2023 Apr;
6(1):pbad004.
PMID: 37007745
The desmoplastic and complex tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) has presented tremendous challenges for developing effective therapeutic strategies. Strategies targeting tumor stroma, albeit with great potential, have met...